Literature DB >> 2060570

Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.

E Lotterer1, M Ruhnke, M Trautmann, R Beyer, F E Bauer.   

Abstract

The systemic availability of oral zidovudine has been studied in 13 patients with the acquired immunodeficiency syndrome (AIDS) dosed either fasting or with breakfast. The mean peak plasma concentration and AUC of zidovudine were significantly 2.8- and 1.4-times higher in fasting patients than in those treated during meal. In both conditions the mean half-life was about 1.5 h and the period of plasma zidovudine concentrations greater than 1 mumol.l-1 was 2 h (NS). It is concluded that if zidovudine is taken on an empty stomach, high peak plasma concentrations and decreased variation in pharmacological parameters may be expected. Whether or not this will influence toxicity and efficacy remains to be shown.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060570     DOI: 10.1007/bf00315215

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

Review 1.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

Review 2.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

Authors:  R Yarchoan; H Mitsuya; C E Myers; S Broder
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

3.  Pharmacokinetics and bioavailability of zidovudine in humans.

Authors:  M R Blum; S H Liao; S S Good; P de Miranda
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

Review 4.  Influence of food and diet on gastrointestinal drug absorption: a review.

Authors:  P G Welling
Journal:  J Pharmacokinet Biopharm       Date:  1977-08

5.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

Review 6.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

Authors:  R W Klecker; J M Collins; R Yarchoan; R Thomas; J F Jenkins; S Broder; C E Myers
Journal:  Clin Pharmacol Ther       Date:  1987-04       Impact factor: 6.875

Review 8.  Influences of diet and nutrition on clinical pharmacokinetics.

Authors:  K E Anderson
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

9.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

10.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

View more
  12 in total

1.  Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.

Authors:  T N Kakuda; L M Page; P L Anderson; K Henry; T W Schacker; F S Rhame; E P Acosta; R C Brundage; C V Fletcher
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.

Authors:  D M Burger; P L Meenhorst; J H Beijnen
Journal:  Pharm World Sci       Date:  1995-03-24

4.  Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS.

Authors:  M Ruhnke; F E Bauer; M Seifert; M Trautmann; H Hille; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.

Authors:  S Kaul; B Christofalo; R H Raymond; M B Stewart; C M Macleod
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of zidovudine. An update.

Authors:  E P Acosta; L M Page; C V Fletcher
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

Review 7.  Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.

Authors:  R M Hoetelmans; D M Burger; P L Meenhorst; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

8.  The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.

Authors:  J Sahai; K Gallicano; G Garber; I McGilveray; N Hawley-Foss; N Turgeon; D W Cameron
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.

Authors:  B N Stretcher; A J Pesce; P T Frame; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 10.  Comparative pharmacokinetics of antiviral nucleoside analogues.

Authors:  G D Morse; M J Shelton; A M O'Donnell
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.